GenScript Biotech Corporation
GenScript Biotech has established itself as a dominant force in the gene synthesis and CGT CDMO market, achieving $959.5 million in 2025 revenue with extraordinary 61.4% year-over-year growth. Its ProBio CDMO subsidiary experienced explosive 309.1% revenue growth to $388.7 million, driven by surging demand for plasmid DNA, viral vector manufacturing, and gene synthesis services. GenScript's unique ecosystem approach, encompassing parent company gene synthesis, ProBio CDMO, and Legend Biotech (cell therapy), creates an integrated CGT value chain.
Strengths: Dominant position in global gene synthesis market with 66,000+ active customers; ProBio CDMO's 309% growth demonstrating exceptional market demand; unique ecosystem spanning from research reagents to commercial cell therapy; Lights-out factory strategy with AI-driven automation; global expansion including new US and European GMP facilities.
Weaknesses: Parent company carrying net losses from legacy R&D investments; geographic exposure to US-China trade tensions and BIOSECURE Act uncertainty; potential conflicts of interest as both CDMO and cell therapy (Legend) parent; integration complexity from rapid expansion across multiple business lines.Read More ▼Show Less ▲
Strengths: Dominant position in global gene synthesis market with 66,000+ active customers; ProBio CDMO's 309% growth demonstrating exceptional market demand; unique ecosystem spanning from research reagents to commercial cell therapy; Lights-out factory strategy with AI-driven automation; global expansion including new US and European GMP facilities.
Weaknesses: Parent company carrying net losses from legacy R&D investments; geographic exposure to US-China trade tensions and BIOSECURE Act uncertainty; potential conflicts of interest as both CDMO and cell therapy (Legend) parent; integration complexity from rapid expansion across multiple business lines.
Listed market data
1548 · HKEX · weeklyHistory →- Market cap
- $9.7 B
- Share price
- ≈ HKD 4.24
- 1Y change
- +109.0%
- Recent change
- -3.9%
- Since first close
- ×23.9
- Revenue (TTM)
- $950 M
10-22 → 10-23
from 2015-12
Financial history
Full market history- 2026-10HKD 33.30$75.9 B0.0%
- 2026-09HKD 33.30$75.9 B-25.8%
- 2026-08HKD 44.86$102 B+32.4%
- 2026-07HKD 33.88$77.3 B+87.6%
- 2026-06HKD 18.06$41.2 B+47.7%
- 2026-05HKD 12.23$27.9 B-10.6%
- 2026-04HKD 13.68$31.2 B-0.3%
- 2026-03HKD 13.72$31.3 B+25.3%
- 2026-02HKD 10.95$25 B-8.3%
- 2026-01HKD 11.94$27.2 B-7.1%
- 2025-12HKD 12.85$29.3 B+3.7%
- 2025-11HKD 12.39$28.3 B—
In the press
All coverage →5 latest headlines1- Genscript Biotech Corporation (1548.HK) stock price, news, quote and history - Yahoo Finance Singaporesg.finance.yahoo.com2026-10-19
- Genscript Biotech (SEHK:1548) Stock Looks Stretched On Its 160% YTD Runfinance.yahoo.com2026-10-17
- Genscript Biotech Corporation: Target Price Consensus and Analysts Recommendations | 2945 | KYG3825B1133 - marketscreener.comwww.marketscreener.com2026-10-15
- Genscript Biotech (DB:G51) Aktienprognose & Analystenprognosen - Simply Wall Streetsimplywall.st2026-10-14
- GenScript Launches Life Sciences Startup PitchFest with NVIDIA to Accelerate Biotech Innovationfinance.yahoo.com2026-10-08
Quick Facts
Headquarters
Nanjing, Jiangsu, China
Founded
2002
Employees
6,000+
Revenue
$959.5M total / $388.7M ProBio CDMO (2025)
Market cap
$9.7 B
Factories
Automated facilities in Nanjing, Zhenjiang CN; Hopewell NJ US; EU sites
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website , GenScript Biotech Official Website | GenScript Biotech China Portal | Legend Biotech Investor Relations (Affiliate) | GenScript ProBio CDMO Platform